# Celularity Inc: financial statements, quarterly

CELU · Nasdaq · CIK 1752828 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/celu.md) · [Financials](/companies/celu/financials.md) · [Filings](/companies/celu/filings.md) · [Insiders](/companies/celu/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/celu/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3.8](/filings/0000950170-24-133799.md) | [12.1 d](/filings/0001641172-25-009319.md) | [14.7](/filings/0001641172-25-026056.md) | [12.1](/filings/0001641172-25-026067.md) | [9.3](/filings/0001493152-25-023467.md) | [18.1 d](/filings/0001493152-26-020424.md) | [11.4](/filings/0001493152-26-044892.md) | [5.7](/filings/0001493152-26-047787.md) | [5.3](/filings/0001493152-25-023467.md) | [4.1 d](/filings/0001493152-26-020424.md) | [3.8](/filings/0001493152-26-044892.md) | [5.4](/filings/0001493152-26-047787.md) |
| Cost of revenue | $m | [3.6](/filings/0000950170-24-133799.md) | [9.6 d](/filings/0001641172-25-009319.md) | [1.6](/filings/0001641172-25-026056.md) | [2.1](/filings/0001641172-25-026067.md) | [3.9](/filings/0001493152-25-023467.md) | [7.3 d](/filings/0001493152-26-020424.md) | [3.6](/filings/0001493152-26-044892.md) | [5.2](/filings/0001493152-26-047787.md) | [3.9](/filings/0001493152-25-023467.md) | [7.4 d](/filings/0001493152-26-020424.md) | [1.5](/filings/0001493152-26-044892.md) | [2.3](/filings/0001493152-26-047787.md) |
| Gross profit | $m | [0.2](/filings/0000950170-24-000474.md) | [2.5 d](/filings/0000950170-24-087886.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.2](/filings/0000950170-24-133799.md) | [(0.3) d](/filings/0001641172-25-009319.md) | [5.8](/filings/0001641172-25-026056.md) | [3.8](/filings/0001641172-25-026067.md) | [3.9](/filings/0001493152-25-023467.md) | [3.8 d](/filings/0001493152-26-020424.md) | [3.7](/filings/0001493152-26-044892.md) | [3.4](/filings/0001493152-26-047787.md) | [4.6](/filings/0001493152-25-023467.md) | [3.3 d](/filings/0001493152-26-020424.md) | [3.0](/filings/0001493152-26-044892.md) | [2.0](/filings/0001493152-26-047787.md) |
| Selling, general and administrative | $m | [10.7](/filings/0000950170-24-133799.md) | [13.1 d](/filings/0001641172-25-009319.md) | [14.0](/filings/0001641172-25-026056.md) | [15.9](/filings/0001641172-25-026067.md) | [12.7](/filings/0001493152-25-023467.md) | [16.1 d](/filings/0001493152-26-020424.md) | [14.3](/filings/0001493152-26-044892.md) | [12.6](/filings/0001493152-26-047787.md) | [9.3](/filings/0001493152-25-023467.md) | [15.1 d](/filings/0001493152-26-020424.md) | [9.2](/filings/0001493152-26-044892.md) | [4.9](/filings/0001493152-26-047787.md) |
| Operating income | $m | [(99.3)](/filings/0000950170-24-133799.md) | [13.3 d](/filings/0001641172-25-009319.md) | [(7.4)](/filings/0001641172-25-026056.md) | [(10.2)](/filings/0001641172-25-026067.md) | [(11.5)](/filings/0001493152-25-023467.md) | [(9.3) d](/filings/0001493152-26-020424.md) | [(10.5)](/filings/0001493152-26-044892.md) | [(15.9)](/filings/0001493152-26-047787.md) | [(12.9)](/filings/0001493152-25-023467.md) | [(22.1) d](/filings/0001493152-26-020424.md) | [(10.1)](/filings/0001493152-26-044892.md) | [(4.2)](/filings/0001493152-26-047787.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | [2.4](/filings/0001493152-26-044892.md) | [1.9](/filings/0001493152-26-047787.md) | not reported | not reported | [0.4](/filings/0001493152-26-044892.md) | [0.2](/filings/0001493152-26-047787.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-133799.md) | [0.0 d](/filings/0001641172-25-009319.md) | [0.0](/filings/0000950170-24-115082.md) | [0.0](/filings/0000950170-24-122493.md) | [0.0](/filings/0000950170-24-133799.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(93.9)](/filings/0000950170-24-133799.md) | [9.5 d](/filings/0001641172-25-009319.md) | [(22.0)](/filings/0001493152-25-023467.md) | [(6.5)](/filings/0001493152-25-023467.md) | [(16.1)](/filings/0001493152-25-023467.md) | [(13.3) d](/filings/0001493152-26-020424.md) | [(19.8)](/filings/0001493152-26-047787.md) | [(24.5)](/filings/0001493152-26-047787.md) | [(23.1)](/filings/0001493152-25-023467.md) | [(24.4) d](/filings/0001493152-26-020424.md) | [0.9](/filings/0001493152-26-047787.md) | [0.7](/filings/0001493152-26-047787.md) |
| Diluted EPS | $ per share | [(4.98)](/filings/0000950170-24-133799.md) | not reported | [(1.03)](/filings/0001641172-25-026056.md) | [(0.30)](/filings/0001641172-25-026067.md) | [(0.73)](/filings/0001493152-25-023467.md) | not reported | [(0.84)](/filings/0001493152-26-044892.md) | [(1.02)](/filings/0001493152-26-047787.md) | [(0.88)](/filings/0001493152-25-023467.md) | not reported | [0.02](/filings/0001493152-26-044892.md) | [0.02](/filings/0001493152-26-047787.md) |
| Basic EPS | $ per share | [(4.98)](/filings/0000950170-24-133799.md) | not reported | [(1.03)](/filings/0001641172-25-026056.md) | [(0.30)](/filings/0001641172-25-026067.md) | [(0.73)](/filings/0001493152-25-023467.md) | not reported | [(0.84)](/filings/0001493152-26-044892.md) | [(1.02)](/filings/0001493152-26-047787.md) | [(0.88)](/filings/0001493152-25-023467.md) | not reported | [0.02](/filings/0001493152-26-044892.md) | [0.02](/filings/0001493152-26-047787.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | period not labelled (2024-07-29) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.2](/filings/0001641172-25-009319.md) | [1.9](/filings/0000950170-24-115082.md) | [0.5](/filings/0000950170-24-122493.md) | not reported | [0.1](/filings/0000950170-24-133799.md) | [0.7](/filings/0001493152-26-020424.md) | [0.3](/filings/0001641172-25-026056.md) | [0.9](/filings/0001641172-25-026067.md) | [0.1](/filings/0001493152-25-023467.md) | [6.2](/filings/0001493152-26-047787.md) | [0.4](/filings/0001493152-26-044892.md) | [0.6](/filings/0001493152-26-047787.md) |
| Current assets | $m | [19.8](/filings/0001641172-25-009319.md) | [22.9](/filings/0000950170-24-115082.md) | [17.7](/filings/0000950170-24-122493.md) | not reported | [14.5](/filings/0000950170-24-133799.md) | [20.6](/filings/0001493152-26-020424.md) | [22.1](/filings/0001641172-25-026056.md) | [17.3](/filings/0001641172-25-026067.md) | [10.6](/filings/0001493152-25-023467.md) | [12.3](/filings/0001493152-26-047787.md) | [6.3](/filings/0001493152-26-044892.md) | [6.4](/filings/0001493152-26-047787.md) |
| Total assets | $m | [144](/filings/0001641172-25-009319.md) | [144](/filings/0000950170-24-115082.md) | [135](/filings/0000950170-24-122493.md) | not reported | [129](/filings/0000950170-24-133799.md) | [133](/filings/0001493152-26-020424.md) | [129](/filings/0001641172-25-026056.md) | [120](/filings/0001641172-25-026067.md) | [114](/filings/0001493152-25-023467.md) | [107](/filings/0001493152-26-047787.md) | [99.5](/filings/0001493152-26-044892.md) | [96.2](/filings/0001493152-26-047787.md) |
| Current liabilities | $m | [67.3](/filings/0001641172-25-009319.md) | [66.0](/filings/0000950170-24-115082.md) | [67.9](/filings/0000950170-24-122493.md) | not reported | [76.2](/filings/0000950170-24-133799.md) | [53.7](/filings/0001493152-26-020424.md) | [58.7](/filings/0001641172-25-026056.md) | [69.2](/filings/0001641172-25-026067.md) | [65.3](/filings/0001493152-25-023467.md) | [80.8](/filings/0001493152-26-047787.md) | [70.6](/filings/0001493152-26-044892.md) | [59.7](/filings/0001493152-26-047787.md) |
| Total liabilities | $m | [103](/filings/0001641172-25-009319.md) | [113](/filings/0000950170-24-115082.md) | [108](/filings/0000950170-24-122493.md) | not reported | [112](/filings/0000950170-24-133799.md) | [124](/filings/0001493152-26-020424.md) | [134](/filings/0001641172-25-026056.md) | [146](/filings/0001641172-25-026067.md) | [134](/filings/0001493152-25-023467.md) | [145](/filings/0001493152-26-047787.md) | [135](/filings/0001493152-26-044892.md) | [132](/filings/0001493152-26-047787.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [39.2](/filings/0000950170-24-133799.md) | [39.8](/filings/0000950170-24-115082.md) | [41.0](/filings/0000950170-24-122493.md) | [42.7](/filings/0000950170-24-087886.md) | [42.6](/filings/0000950170-24-133799.md) | not reported | [6.3](/filings/0001641172-25-026056.md) | [6.3](/filings/0001641172-25-026067.md) | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [17.2](/filings/0000950170-24-087886.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [41.0](/filings/0001493152-26-020424.md) | [31.2](/filings/0001493152-25-023467.md) | [27.8](/filings/0001493152-25-023467.md) | not reported | [17.3](/filings/0001493152-25-023467.md) | [8.8](/filings/0001493152-26-047787.md) | [(5.5)](/filings/0001493152-26-047787.md) | [(25.5)](/filings/0001493152-26-047787.md) | [(20.1)](/filings/0001493152-25-023467.md) | [(38.1)](/filings/0001493152-26-047787.md) | [(35.3)](/filings/0001493152-26-047787.md) | [(35.5)](/filings/0001493152-26-047787.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent, us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(8,322) d](/filings/0000950170-24-133799.md) | [(4,341) d](/filings/0001641172-25-009319.md) | [(4,403)](/filings/0001641172-25-026056.md) | [(3,448) d](/filings/0001641172-25-026067.md) | [(144) d](/filings/0001493152-25-023467.md) | [1,594 d](/filings/0001493152-26-020424.md) | [(2,993)](/filings/0001493152-26-044892.md) | [(999) d](/filings/0001493152-26-047787.md) | [(4,159) d](/filings/0001493152-25-023467.md) | [(5,103) d](/filings/0001493152-26-020424.md) | [1,447](/filings/0001493152-26-044892.md) | [(1,108) d](/filings/0001493152-26-047787.md) |
| Capital expenditure | $k | [228 d](/filings/0000950170-24-133799.md) | [580 d](/filings/0001641172-25-009319.md) | [39.0](/filings/0001641172-25-026056.md) | [31.0 d](/filings/0001641172-25-026067.md) | [0.0 d](/filings/0001493152-25-023467.md) | [91.0 d](/filings/0001493152-26-020424.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [151](/filings/0000950170-24-000474.md) | [15.5](/filings/0000950170-24-115082.md) | [17.7](/filings/0000950170-24-122493.md) | [18.8](/filings/0000950170-24-133799.md) | [21.4](/filings/0001641172-25-026056.md) | [21.8](/filings/0001641172-25-026067.md) | [22.0](/filings/0001493152-25-023467.md) | [23.5](/filings/0001493152-26-044892.md) | [24.0](/filings/0001493152-26-047787.md) | [26.3](/filings/0001493152-25-023467.md) | [30.3](/filings/0001493152-26-044892.md) | [29.3](/filings/0001493152-26-047787.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,450,679 at 2026-10-19, from the cover of the [10-Q filed 2026-10-20](/filings/0001493152-26-047787.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.